menu
    • menu
    [{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"SNBL","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ SNBL","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ SNBL"}]

    Find Clinical Drug Pipeline Developments & Deals by Satsuma Pharmaceuticals

    Menu

    Satsuma Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satsuma and SNBL Receive FDA Acceptance for NDA Resubmission of STS101 for Migraine

                            Details : STS101 (dihydroergotamine nasal powder). STS101 is an investigational product which is being evaluated for migraine with or without aura in adults.

                            Product Name : STS101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 26, 2024

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satsuma Resubmits NDA for STS101 Nasal Powder for Migraine Treatment

                            Details : STS101 (dihydroergotamine nasal powder). STS101 is an investigational product which is being evaluated for migraine with or without aura in adults.

                            Product Name : STS101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 30, 2024

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            US FDA Declines to Approve Shin Nippon Biomedical's Migraine Drug

                            Details : STS101 (dihydroergotamine nasal powder). STS101 is an investigational product which is being evaluated in phase 1 clinical trials for the acute treatment of migraine with or without aura in adults.

                            Product Name : STS101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 18, 2024

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihy...

                            Details : STS101 (dihydroergotamine mesylate) constricts the pain-producing intracranial extracerebral blood vessels at the 5-HT1B receptors and inhibiting the trigeminal neurotransmission at the peripheral and central 5-HT1D receptors.

                            Product Name : STS101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 18, 2023

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : SNBL

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            SNBL to Acquire Satsuma Pharmaceuticals

                            Details : The acquisition will expand SNBL's pipeline by including STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine.

                            Product Name : STS101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 16, 2023

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : SNBL

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update

                            Details : STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and inject...

                            Product Name : STS101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 20, 2022

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment ...

                            Details : STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device.

                            Product Name : STS101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 14, 2022

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment ...

                            Details : STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device.

                            Product Name : STS101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 14, 2022

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-ter...

                            Details : Subjects administered STS101 (dihydroergotamine mesylate) to treat their migraine attacks for as long as 18 months in a real-world setting, confirm the favorable safety and tolerability profile of STS101 observed to date in more than 1,600 clinical trial...

                            Product Name : STS101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 20, 2022

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Satsuma Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society's ...

                            Details : STS101 (dihydroergotamine mesylate) is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device.

                            Product Name : STS101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 06, 2022

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth